A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

Cytomegalovirus (CMV) Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients

Status Completed

Clinical Trial Summary

This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. A placebo will look like marivabir or valganciclovir but will not have any medicine in it. After treatment, each participant will be followed up for up to 12 weeks. Participants will visit their study clinic up to 18 times during the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02927067
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	April 14, 2017
Completion date	July 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05319353` - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection	Phase 3
Completed	`NCT05571137` - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
Not yet recruiting	`NCT06243731` - A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Not yet recruiting	`NCT06439342` - A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections	Phase 3
Completed	`NCT05576805` - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
Not yet recruiting	`NCT06213974` - A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Completed	`NCT02775240` - Study of SHP620 (Maribavir) in Healthy Adults	Phase 1
Completed	`NCT01611974` - Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients	Phase 2
Completed	`NCT05137717` - A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection	Phase 3
Completed	`NCT02931539` - Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir	Phase 3